Incyte Corporation (INCY) Stock

Incyte Corporation trades at a P/E ratio of 19.55, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 11.99 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.12 suggests the stock may be undervalued relative to its growth rate.

With a beta of 0.75, Incyte Corporation is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.87 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Incyte Corporation achieves a profit margin of 19.00%, meaning it retains $19.00 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 25.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 24.30% and ROA at 11.50%, the company generates strong returns on invested capital.

Incyte Corporation's revenue grew by 16.50% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 6.70% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Incyte Corporation has a market capitalization of $16.4B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 195.28M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.

Incyte Corporation's book value per share is $21.49, while the current stock price is $90.18, resulting in a price-to-book (P/B) ratio of 4.20. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

27 analysts cover INCY with 44% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $83.38 implies -7.5% downside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:2 Strong Buy, 10 Buy, 13 Hold, 1 Sell, 1 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.